Allogene Therapeutics, Inc. (ALLO)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch ALLO
See up to 3 months of ALLO. The 7-day demo opens the 1M and 3M ranges and puts ALLO on your watchlist.
Start 7-day demoLatest ALLO insider trades
About Allogene Therapeutics, Inc. (ALLO)
The SEC lists Allogene Therapeutics, Inc. under CIK 0001737287, in biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
ALLO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 29,697 | $63K |
ALLO insider transactions (Form 4)
4529 Form 4 filings on record, the earliest from Oct 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Earl Martin Douglas - Officer | Open-market sale | Common Stock | 29,697 footnote F1 | $2.12 | $63K | |
| ||||||
 Zachary Roberts - Officer | Grant or award | Restricted Stock Unit | 134,530 | $0.00 | - | |
| Zachary Roberts - Officer | Grant or award | Stock Option (Right to buy) | 476,190 | $0.00 | - | |
| Joshua A. Kazam - Director | Grant or award | Restricted Stock Unit | 95,400 | $0.00 | - | |
| Joshua A. Kazam - Director | Option exercise | Common Stock | 47,700 | $0.00 | - | |
| Joshua A. Kazam - Director | Option exercise | Restricted Stock Unit | 47,700 | $0.00 | - | |
| Deborah M. Messemer - Director | Grant or award | Restricted Stock Unit | 95,400 | $0.00 | - | |
 Stephen Mayo - Director | Grant or award | Stock Option (Right to buy) | 144,400 | $0.00 | - | |
 Vicki L. Sato - Director | Grant or award | Restricted Stock Unit | 95,400 | $0.00 | - | |
 Owen N. Witte - Director | Grant or award | Restricted Stock Unit | 95,400 | $0.00 | - | |
| Franz B. Humer - Director | Grant or award | Restricted Stock Unit | 95,400 | $0.00 | - | |
| Elizabeth A. Barrett - Director | Grant or award | Restricted Stock Unit | 95,400 | $0.00 | - | |
| Annie Yoshiyama - Officer | Open-market sale | Common Stock | 9,586 footnote F1 | $2.31 footnote F2 | $22K | |
| ||||||
| Benjamin Machinas Beneski - Officer | Open-market sale | Common Stock | 2,867 footnote F1 | $2.50 | $7K | |
| ||||||
| Benjamin Machinas Beneski - Officer | Open-market sale | Common Stock | 4,835 footnote F1 | $2.47 footnote F2 | $12K | |
| ||||||
| David D. Chang - Officer | Open-market sale | Common Stock | 47,763 footnote F1 | $2.47 | $118K | |
| ||||||
| Benjamin Machinas Beneski - Officer | Open-market sale | Common Stock | 7,132 footnote F1 | $2.60 footnote F2 | $19K | |
| ||||||
| Benjamin Machinas Beneski - Officer | Open-market sale | Common Stock | 7,549 footnote F1 | $1.73 footnote F2 | $13K | |
| Benjamin Machinas Beneski - Officer | Grant or award | Stock Option (Right to buy) | 373,757 | $0.00 | - | |
| Benjamin Machinas Beneski - Officer | Grant or award | Restricted Stock Unit | 105,720 | $0.00 | - | |
| ||||||
| David D. Chang - Officer | Open-market sale | Common Stock | 95,269 footnote F1 | $1.80 footnote F2 | $171K | |
| David D. Chang - Officer | Grant or award | Stock Option (Right to buy) | 1,387,931 | $0.00 | - | |
| David D. Chang - Officer | Grant or award | Restricted Stock Unit | 392,586 | $0.00 | - | |
| ||||||
 Geoffrey M. Parker - Officer | Open-market sale | Common Stock | 24,001 footnote F1 | $1.76 footnote F2 | $42K | |
| Geoffrey M. Parker - Officer | Grant or award | Stock Option (Right to buy) | 539,072 | $0.00 | - | |
| Geoffrey M. Parker - Officer | Grant or award | Restricted Stock Unit | 152,480 | $0.00 | - | |
| ||||||
| Earl Martin Douglas - Officer | Open-market sale | Common Stock | 22,900 footnote F1 | $1.76 footnote F2 | $40K | |
| Earl Martin Douglas - Officer | Grant or award | Stock Option (Right to buy) | 539,072 | $0.00 | - | |
| Earl Martin Douglas - Officer | Grant or award | Restricted Stock Unit | 152,480 | $0.00 | - | |
| ||||||
| Annie Yoshiyama - Officer | Open-market sale | Common Stock | 4,167 footnote F1 | $1.72 footnote F2 | $7K | |
| Annie Yoshiyama - Officer | Grant or award | Stock Option (Right to buy) | 179,691 | $0.00 | - | |
| Annie Yoshiyama - Officer | Grant or award | Restricted Stock Unit | 50,827 | $0.00 | - | |
| ||||||
| Zachary Roberts - Officer | Open-market sale | Common Stock | 35,700 footnote F1 | $1.77 footnote F2 | $63K | |
| Zachary Roberts - Officer | Grant or award | Stock Option (Right to buy) | 718,763 | $0.00 | - | |
| Zachary Roberts - Officer | Grant or award | Restricted Stock Unit | 203,307 | $0.00 | - | |
| ||||||
 Arie Belldegrun - Director | Grant or award | Stock Option (Right to buy) | 929,913 | $0.00 | - | |
| Arie Belldegrun - Director | Grant or award | Restricted Stock Unit | 263,033 | $0.00 | - | |
| Zachary Roberts - Officer | Open-market sale | Common Stock | 26,269 footnote F1 | $1.56 | $41K | |
| ||||||
| Benjamin Machinas Beneski - Officer | Open-market sale | Common Stock | 786 footnote F1 | $1.22 footnote F2 | $959 | |
| ||||||
| Geoffrey M. Parker - Officer | Open-market sale | Common Stock | 36,744 footnote F1 | $1.26 | $46K | |
| ||||||
| Joshua A. Kazam - Director | Grant or award | Restricted Stock Unit | 94,500 | $0.00 | - | |
| Vicki L. Sato - Director | Grant or award | Stock Option (Right to buy) | 144,400 | $0.00 | - | |
| Deborah M. Messemer - Director | Open-market sale | Common Stock | 9,136 | $2.18 | $20K | |
| Franz B. Humer - Director | Open-market sale | Common Stock | 9,221 | $2.16 | $20K | |
| Geoffrey M. Parker - Officer | Tax withholding / forfeiture | Common Stock | 36,404 | $2.84 | $103K | |
Item 5.02
Item 2.02, 9.01
Item 5.07, 8.01
Item 5.02
Recent ALLO Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Douglas Earl Martin | Officer | 29,697 | $63K | View on EDGAR | |
| - | - | - | - |
ALLO insider trading FAQ
What is the latest insider trade for ALLO?
Allogene Therapeutics, Inc. (ALLO) had 1 insider filing in the last 90 days, with the most recent on 2026-08-25. The full record for ALLO runs to 29 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ALLO stock?
No insider purchases of ALLO were filed in the last 90 days.
How many insiders are selling ALLO stock?
1 insider sale of ALLO was filed in the last 90 days, totaling $63K.
Where can I see ALLO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ALLO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Earl Martin Douglas view on EDGAR
- - Zachary Roberts view on EDGAR
- - Joshua A. Kazam view on EDGAR
- - Deborah M. Messemer view on EDGAR
- - Stephen Mayo view on EDGAR
- - Vicki L. Sato view on EDGAR
- - Owen N. Witte view on EDGAR
- - Franz B. Humer view on EDGAR
- - Elizabeth A. Barrett view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ALLO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ALLO with a 7-day demo
- ALLO on your watchlist
- Every ALLO Form 4 filing on record
- Up to 3 months of ALLO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
